Skip to main content
. 2009 Aug;12(4):259–267. doi: 10.1089/rej.2009.0854

FIG. 5.

FIG. 5.

Effect of Ndi1 treatment on the TH-positive cells in the substantia nigra of the chronic parkinsonian mice. Representative photomicrographs of TH staining of brain sections illustrate the density of TH-positive cells in the left and right substantia nigra between the control and chronic MPTP/probenecid-treated mice without or with 8-month rAAV-NDI1 pretreatment (right hemisphere, shown by arrow). Scale bar, 500 μm. The results are compared in the histograms for the control group (N = 6), the chronic MPTP/probenecid-treated group (N = 8), and the rAAV-NDI1-treated group (N = 10). Chronic systemic MPTP/probenecid treatment resulted in a substantial loss of TH-immunoreactivity bilaterally in the substantia nigra 5 weeks posttreatment when compared with the control animals. When mice were preinjected with rAAV-NDI1 in the right substantia nigra (arrow) 8 months prior to MPTP/probenecid treatment, near-normal TH-immunoreactivity was observed in the Ndi1-pretreated side of substantia nigra 5 weeks after the induction of chronic Parkinsonism. ***p < 0.001. TH, Tyrosine hydroxylase; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Prob., probenecid.